GW Pharmaceuticals to Present at Upcoming Investor Conferences
November 22 2017 - 7:00AM
– 29th Annual Piper Jaffray Healthcare Conference
on November 29, 2017 –
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, today announced that Justin Gover, GW’s Chief
Executive Officer, will be presenting at the 29th Annual Piper
Jaffray Healthcare Conference on Wednesday, November 29, 2017 at
12:00 p.m. ET at the Lotte New York Palace, New York, NY and at the
Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on
Thursday, November 30, 2017 at 2:00 p.m ET at the Boston Harbor
Hotel in Boston, MA.
A live audio webcast of the presentations will
be available through GW’s corporate website at www.gwpharm.com on
the Investors section under Events & Presentations. A replay
will be available soon after the live presentation.
About GW Pharmaceuticals
plc
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW, along with its U.S.
subsidiary Greenwich Biosciences, is advancing an orphan drug
program in the field of childhood epilepsy with a focus on
Epidiolex (cannabidiol), for which GW has submitted an NDA to the
FDA for the adjunctive treatment of LGS and Dravet syndrome. The
Company continues to evaluate Epidiolex in additional epilepsy
conditions and currently has ongoing clinical trials in Tuberous
Sclerosis Complex and Infantile Spasms. GW commercialized the
world’s first plant-derived cannabinoid prescription drug, Sativex®
(nabiximols), which is approved for the treatment of spasticity due
to multiple sclerosis in numerous countries outside the United
States. The Company has a deep pipeline of additional cannabinoid
product candidates which includes compounds in Phase 1 and 2 trials
for glioblastoma, schizophrenia and epilepsy. For further
information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917
280 2424 / 401 500 6570 |
|
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Sep 2023 to Sep 2024